Relapse following initial remission and subsequent outcome for children with relapsed acute myeloid leukemia on the AAML0531 phase III study of gemtuzumab ozogamicin: A report from the children's oncology group

Category Primary study
JournalBlood
Year 2016
This article has no abstract
Epistemonikos ID: 2527b286407a3f8ae0c6b54cb6204c0ba19f3030
First added on: Feb 08, 2025